Searchicon: search

The NXT step in
vaccine innovation

Nobivac NXT® vaccines combine a 0.5 mL dose with a
non-adjuvanted formulation for a safe and comfortable
vaccination experience.1-7

Experience NXT-generation safety and protection

Designed with
safety in mind

No adjuvants, preservatives, thimerosal,
or antibiotics1-7

One 0.5 mL dose
across all vaccines

Supports comfort and ease
of administration4-8

Protection without compromise

Stimulates a powerful multi-layered protective immune response, without the need for an adjuvant1-3,9

Meet the growing Nobivac NXT® family

FIRST AND ONLY

0.5 mL non-adjuvanted rabies vaccine 
for both cats and dogs4,5
100% of cats and dogs were protected from rabies 3 years after vaccination1

Labeled 1- or 3-year DOI4,5

FIRST AND ONLY

0.5 mL non-adjuvanted vaccine for
canine flu H3N26
Significantly reduced viral shedding and coughing in exposed dogs2

Labeled 1-year DOI6

FIRST AND ONLY

0.5 mL non-adjuvanted FeLV vaccine with a 2-year label claim7
100% of cats were protected against persistent viremia in 2 challenge studies3

Labeled 2-year DOI7

Explore Nobivac NXT® vaccines

icon: arrow-right

CANINE & FELINE

Nobivac NXT® 1-Rabies

The first and only 0.5 mL non-adjuvanted rabies vaccine for cats and dogs.4,5

icon: arrow-right

CANINE & FELINE

Nobivac NXT® 3-Rabies

The first and only 0.5 mL non-adjuvanted rabies vaccine for cats and dogs.4,5

icon: arrow-right

CANINE

Nobivac NXT® CIV

The first and only non-adjuvanted canine flu H3N2 vaccine.6 Significantly reduces viral shedding and coughing in exposed dogs.2

icon: arrow-right

Feline

Nobivac NXT® FeLV

The first and only non-adjuvanted feline leukemia virus (FeLV) vaccine with a 2-year label duration of immunity claim.7,18

Nobivac NXT®: Leading the way in vaccine experience

Click any image to view an enlarged version

Supports a positive vaccination experience for pets, their owners, and your practice

For pets

Designed with comfort in mind4-8

For pet owners

Helping to strengthen trust with each positive vaccination experience

For your practice

Simplified ordering and storage

Something new is coming.
Be the first
to know.

Get early access to disease insights, clinical resources, and product news.

Subscribe

Frequently Asked Questions

Which vaccines are part of the Nobivac NXT® range?

icon: plus icon: minus

The Nobivac NXT®portfolio includes Nobivac NXT® Rabies for both cats and dogs, Nobivac NXT® Canine Flu H3N2 for canine influenza H3N2, and Nobivac NXT® FeLV for feline leukemia virus (FeLV). All Nobivac NXT® vaccines are non-adjuvanted and administered as a 0.5 mL dose.4-7

Are Nobivac NXT® vaccines safe for dogs and cats?

icon: plus icon: minus

Yes. Clinical studies have demonstrated the safety and tolerability profile of Nobivac NXT® vaccines. They have been proven safe across a variety of breeds and ages.1-3 For further safety information, please refer to the relevant product label.

Do Nobivac NXT® vaccines contain adjuvants, preservatives, thimerosal, or antibiotics?

icon: plus icon: minus

No. Designed with safety in mind, Nobivac NXT® vaccines contain no adjuvants, preservatives, thimerosal, or antibiotics.1,4-7,20-25

Vaccines containing adjuvants are associated with diverse reactions in dogs and cats, including discomfort, lethargy, persistent granulomas, and other potential complications.26,27 Additionally, residual proteins such as bovine serum albumin (BSA) may contribute to post-vaccination reactions.20,23 Nobivac NXT® vaccines are manufactured using a serum-free process, enabling formulations with low levels of residual BSA.1,3

How long are pets protected after receiving a Nobivac NXT® vaccine?

icon: plus icon: minus

Duration of immunity for Nobivac NXT® vaccines varies. Nobivac NXT® 3-Rabies protects dogs and cats for at least 3 years after a repeat dose, while Nobivac NXT® 1-Rabies provides at least 1 year of protection.4,5 Nobivac NXT® Canine Flu H3N2 has a 1-year labeled duration of immunity6 and Nobivac NXT® FeLV has a 2-year labeled duration of immunity.7

Abbreviations:

BSA, bovine serum albumin; DOI, duration of immunity; FeLV, feline leukemia virus; H3N2, hemagglutinin type 3 neuraminidase type 2.

References:

  1. Stachura K, Davis R, Carritt K, Mogler M, Xu Z, Tarpey I. A novel, safe, non-adjuvanted alphavirus RNA particle vaccine expressing the rabies virus glycoprotein induces a three-year duration of immunity in dogs and cats after a single vaccine dose. Vaccines (Basel). 2025;13(12):1176.
  2. Classe HM, Dant JC, Mogler M, et al. Efficacy and safety in dogs following administration of an alphavirus RNA particle canine influenza H3N2 vaccine. Vaccines (Basel). 2024;12(10):1138.
  3. Carritt K, Davis R, Stachura K, et al. A novel, safe, non-adjuvanted alphavirus replicon-based vaccine expressing the feline leukemia virus envelope protein protects against virulent FeLV challenge. Vaccines (Basel). 2025;13(7):697.
  4. Nobivac NXT® 3-Rabies Product label. Merck Animal Health.
  5. Nobivac NXT® 1-Rabies Product label. Merck Animal Health.
  6. Nobivac NXT® Canine Flu H3N2 Product label. Merck Animal Health.
  7. Nobivac NXT® FeLV Product label. Merck Animal Health.
  8. Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996.
  9. Natesan K, Isloor S, Vinayagamurthy B, Ramakrishnaiah S, Doddamane R, Fooks AR. Developments in rabies vaccines: the path traversed from Pasteur to the modern era of immunization. Vaccines (Basel). 2023;11(4):756.
  10. PUREVAX® Feline Rabies 3 YR. Product label. Boehringer Ingelheim Animal Health USA Inc.
  11. Vanguard® Rabies 3 Year. Product label. Zoetis, Inc.
  12. Rabvac® 3. Product label. Elanco US Inc.
  13. IMRAB® 3. Product label. Boehringer Ingelheim Animal Health USA Inc.
  14. IMRAB® 3 TF. Product label. Boehringer Ingelheim Animal Health USA Inc.
  15. TruCan TM Ultra CIV H3N2/H3N8. Product label. Elanco US Inc.
  16. Vanguard® CIV H3N2/H3N8. Product label. Zoetis, Inc.
  17. PUREVAX® Recombinant FeLV. Product label. Boehringer Ingelheim Animal Health USA Inc.
  18. Vanguard® Feline FeLV. Product label. Zoetis, Inc.
  19. TruFel™ Ultra FeLV. Product label. Elanco US Inc.
  20. Franco J, Aryal UK, HogenEsch H, Moore GE. Proteomic analysis of canine vaccines. Am J Vet Res. 2023;84(3):ajvr.22.11.0192.
  21. Hartmann K, Egberink H, Möstl K, et al. Feline injection-site sarcoma and other adverse reactions to vaccination in cats. Viruses. 2023;15(8):1708.
  22. Yoshida M, Mizukami K, Hisasue M, et al. Anaphylaxis after rabies vaccination for dogs in Japan. J Vet Med Sci. 2021;83(8):1202-1205.
  23. Moore GE, Morrison J, Saito EK, Spofford N, Yang M. Breed, smaller weight, and multiple injections are associated with increased adverse event reports within three days following canine vaccine administration. J Am Vet Med Assoc. 2023;261(11):1653-1659.
  24. Moore GE, DeSantis-Kerr AC, Guptill LF, Glickman NW, Lewis HB, Glickman LT. Adverse events after vaccine administration in cats: 2560 cases (2002-2005). J Am Vet Med Assoc. 2007;231(1):94-100.
  25. Yoshida M, Mizukami K, Hisasue M, et al. Anaphylaxis after vaccination for cats in Japan. J Vet Med Sci. 2022;84(1):149-152. doi:10.1292/jvms.21-0437.
  26. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med. 2003;17(3):273-281.
  27. Gershwin LJ. Adverse reactions to vaccination: From anaphylaxis to autoimmunity. Vet Clin North Am Small Anim Pract. 2018;48(2):279-290.

All trademarks are property of their respective owners.